Oligonucleotide Synthesis Market– Statistics And Analysis & Forecast To 2025

Posted by Mrudula Anil Karmarkar on April 14th, 2021

The global oligonucleotide synthesis market size is expected to reach USD 3.9 billion by 2025 at a 12.4% CAGR during the forecast period, according to a new report by Grand View Research, Inc. Continuous rise in usage of oligonucleotide synthesis across various aspects of human health management, from molecular diagnostics to therapeutics, is spurring revenue growth.

Biopharmaceutical innovators are at the forefront of the human response to the coronavirus pandemic. A significant number of major biotech firms are in the midst of a race to investigate the Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the speed of response to SARS/MERs etc, the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are being put into the R&D. With multiple candidates in trial, the public and private sectors are anticipated to work in unison for the foreseeable period, until a vaccine is developed for Covid-19. The report will account for Covid19 as a key market contributor.

The recent success of oligonucleotide-based drugs in medicine due to increase in number of FDA-approved products is anticipated to boost revenue generation in this market. As of September 2017, there are six approved oligonucleotide therapeutic products.

A substantial number of oligos are being investigated for their usage in targeting various infectious diseases. For instance, dsDNA thioaptamers are reported to target the ribonuclease H (RNase H) domain of HIV-RT and are demonstrated to inhibit HIV-RT when used in vitro.

In addition, demand for cancer-related thioapatmers that can detect presence as well as target tumor growth factors, such as TGF-β, is on a continuous rise. This, in turn, has led to increase in investments for exploring the significance of custom oligonucleotide synthesis in cancer research.

Oligonucleotide Synthesis Market Report Highlights

• Growing usage of ready as well as custom oligos in genomic research is expected to drive the market
• Column-based oligos have a higher per nucleotide base price compared to array-based oligos. As a result, column-based oligos accounted for the largest revenue share by product type in 2017
• North America dominated the global market in 2017 as a result of large investments in genetic research and effective regulatory policies that encourage gene-based research activities in the region
• Asian countries are expected to emerge as a key source of lucrative revenue generation during the forecast period. This is primarily due to growing awareness as well as popularity of genetic medicine among the population
• The market is highly fragmented, with the presence of several major and emerging players offering DNAs, RNAs, and other oligos. Market competition is anticipated to increase with growing number of new entrants offering customized services
• Some of the key companies in the market are BioAutomation; Integrated DNA Technologies, Inc.; LGC Biosearch Technologies; Agilent Technologies; GE Healthcare Dharmacon Inc.; and Gene Scripts.

Oligonucleotide synthesis is an integral part of several ongoing genetic research studies. Rising investments in genetic research are anticipated to boost demand for a custom synthesis of different classes of oligos including decoys, aptamers, immunostimulatory, antisense, siRNA, and miRNA.

Several major and emerging oligonucleotides manufacturers are expanding their businesses through collaboration with pharmaceutical manufacturers. For instance, in June 2017, CordenPharma International signed a strategic collaboration with GE Healthcare Dharmacon Inc. for the development of an end-to-end oligonucleotide-based drug discovery solution.

A substantial number of oligos are under late phase clinical trials targeting various conditions such as cancer, cardiovascular diseases, muscle dystrophies, and ocular disorders. This anticipated regulatory approval for multiple oligonucleotide-based therapies is expected to propel the market.

Marketing approaches implemented in this market include direct selling and selling via distributors in specific countries. The market is expected to benefit from the constant growth of genomics and gene editing markets, as advancement in genetic tools would simplify the synthesis of oligonucleotides.

Have a Query? Ask Our Expert:

https://www.grandviewresearch.com/inquiry/5275/ibb

Some key companies operating in the market are Thermo Fisher Scientific, Inc.; Merck - Co., Inc.; GE Healthcare Dharmacon Inc.; Agilent Technologies; Bio-synthesis; Kaneka Eurogentec S.A.; Integrated DNA Technologies, Inc.; BioAutomation; and LGC Biosearch Technologies. The market is highly competitive due to rigorous strategies adopted by these players to capture a greater market share.

Various strategies adopted by these competitors include the acquisition of players in emerging markets, distribution partnerships, and collaboration for the development of novel technologies and products. For instance, in February 2017, Integrated DNA Technologies acquired GeneWorks Pty Ltd., an oligonucleotide manufacturer in Australia through its Singapore-based subsidiary.

Grand View Research has segmented the global oligonucleotide synthesis market on the basis of product, application, end use:

Oligonucleotide Synthesis Product Outlook (Revenue, USD Million, 2014 - 2025)

• Oligonucleotides

o    Oligonucleotides, By Product Type

o    Column-based Oligos

o    Array-based Oligos

o    Oligonucleotides, By Nucleic Acid Type

o    DNA

o    RNA

• Equipment
• Reagents
• Services

o    Oligo Synthesis

o    25 nmol

o    50 nmol

o    200 nmol

o    1000 nmol

o    10,000 nmol

o    Purification

o    Modification

Oligonucleotide Synthesis Application Outlook (Revenue, USD Million, 2014 - 2025)

• PCR Primers
• PCR Assays and Panels
• Sequencing
• DNA Microarrays
• Fluorescence In Situ Hybridization (FISH)
• Antisense Oligonucleotides
• Other Applications

Oligonucleotide Synthesis End-use Outlook (Revenue, USD Million, 2014 - 2025)

• Academic Research Institutes
• Diagnostic Laboratories
• Pharmaceutical & Biotechnology Companies

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information:www.grandviewresearch.com